PDS Biotechnology Corporation

NasdaqCM:PDSB Stock Report

Market Cap: US$102.2m

PDS Biotechnology Management

Management criteria checks 2/4

PDS Biotechnology's CEO is Frank Bedu-Addo, appointed in Mar 2019, has a tenure of 5.25 years. total yearly compensation is $5.01M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 1.88% of the company’s shares, worth $1.92M. The average tenure of the management team and the board of directors is 2 years and 5.3 years respectively.

Key information

Frank Bedu-Addo

Chief executive officer

US$5.0m

Total compensation

CEO salary percentage11.6%
CEO tenure5.3yrs
CEO ownership1.9%
Management average tenure2yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech jumps 13% as FDA clears further development of lead asset

Oct 03

PDS Biotechnology files for $150 mixed shelf offering

Aug 24

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

Aug 04

PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

Jul 08
PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

May 27

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

Feb 22

PDS Biotech: Looking Attractive Despite 52-Week High Price

Sep 19

PDS Biotech under pressure after pricing equity offering at $8.50

Jun 15

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

Feb 03

PDS Biotechnology gives new CFO ~202K stock grant

Jan 06

PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer

Nov 10

CEO Compensation Analysis

How has Frank Bedu-Addo's remuneration changed compared to PDS Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$5mUS$580k

-US$43m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$2mUS$540k

-US$41m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$7mUS$475k

-US$17m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$815kUS$450k

-US$15m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$3mUS$356k

-US$7m

Compensation vs Market: Frank's total compensation ($USD5.01M) is above average for companies of similar size in the US market ($USD674.46K).

Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.

CEO

Frank Bedu-Addo (59 yo)

5.3yrs

Tenure

US$5,011,234

Compensation

Dr. Frank K. Bedu-Addo, Ph D., served as Interim Principal Financial Officer for PDS Biotechnology Corporation since September 30, 2021 until October 2021. He serves as Chief Executive Officer of PDS Biote...

Leadership Team

NamePositionTenureCompensationOwnership
Frank Bedu-Addo
President5.3yrsUS$5.01m1.88%
$ 1.9m
Gregory Conn
Chief Scientific Officer5.3yrsUS$1.68m0.34%
$ 344.2k
Lars Boesgaard
Principal Financial & Accounting Officer and CFOless than a yearno datano data
Stephan Toutain
Chief Operating Officerless than a yearno datano data
Joe Dervan
VP of Research & Development3.4yrsno datano data
Deanne Randolph
Head of Investor Relationsno datano datano data
Spencer Brown
Senior VP2yrsno data0%
$ 0
Kirk Shepard
Chief Medical Officerless than a yearno datano data
Janetta Trochimiuk
Controllerno datano datano data

2.0yrs

Average Tenure

59yo

Average Age

Experienced Management: PDSB's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frank Bedu-Addo
President5.3yrsUS$5.01m1.88%
$ 1.9m
Gregory Freitag
Independent Director5.3yrsUS$105.49k0.13%
$ 128.5k
Richard Sykes
Independent Director5.3yrsUS$94.49k1.21%
$ 1.2m
Stephen Glover
Independent Chairman5.2yrsUS$135.99k0.17%
$ 177.7k
Jerold Woodward
Member of Scientific Advisory Boardno datano datano data
Kamil Ali-Jackson
Independent Director4.3yrsUS$106.49k0.032%
$ 32.8k
Mark Einstein
Member of Scientific Advisory Boardno datano datano data
Darron Brown
Member of Scientific Advisory Boardno datano datano data
Leaf Huang
Member of Scientific Advisory Boardno datano datano data
Samir Khleif
Member of Scientific Advisory Boardno datano datano data
Lisa Rohan
Chair of the Scientific Advisory Boardno datano datano data
Neil Gross
Member of Scientific Advisory Boardno datano datano data

5.3yrs

Average Tenure

63yo

Average Age

Experienced Board: PDSB's board of directors are considered experienced (5.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.